Concomitant Intranasal Antihistamine and Corticosteroid in Stepwise Treatment Strategy for Allergic Rhinitis

Study Overview
=================
Brief Summary
-----------------
Patients with perennial allergic rhinitis whose symptoms are not controlled (visual analogue scale [VAS] ≥5) by 2-week treatment with intranasal corticosteroid will receive concomitant intranasal antihistamine and corticosteroid for 2 weeks. After 2-week treatment, changes in clinical parameters including VAS, total nasal symptom score (TNSS), total ocular symptom score (TOSS), rhinoconjunctivitis quality-of-life questionnaires (RQLQ) will be evaluated.

Detailed Description
-----------------
Patients with perennial allergic rhinitis whose symptoms are not controlled (visual analogue scale [VAS] ≥5) by 2-week treatment with intranasal corticosteroid will receive concomitant intranasal antihistamine and corticosteroid. In addition to VAS, total nasal symptom score (TNSS), total ocular symptom score (TOSS), rhinoconjunctivitis quality-of-life questionnaires (RQLQ) will be measured before treatment (baseline) and 2 week after treatment. The differences between parameters before treatment and those after 2-week treatment will be statistically analyzed using paired student t test, and p<0.05 was considered statistically significant.

Official Title
-----------------
Therapeutic Role of Concomitant Intranasal Antihistamine and Corticosteroid in Patient With Perennial Allergic Rhinitis Whose Symptoms Are Not Controlled With Intranasal Corticosteroid

Conditions
-----------------
Allergic Rhinitis

Intervention / Treatment
-----------------
* Drug: concomitant intranasal antihistamine and corticosteroid


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Perinnial allergic rhinitis diagnosed by a doctor Positive for one or more of inhalant perinneal allergen in skin prick test or serum specific IgE measurement Age: 19 years or older Allergic rhinitis symptoms not controlled (VAS ≥5) by 2-week treatment with intranasal corticosteroid Exclusion Criteria: Compliance for one or more drugs in last 2 weeks: <80% Use of oral corticosteroid, oral or intranasal decongestant in last 2 weeks Initiation of allergen-specific immunotherapy in last 12 months Seasonal allergic rhinitis Chronic rhinosinusitis other than allergic rhinitis Nasal polyposis Comorbid diseases including infectious, respiratory, cardiologic, renal, gastrointestinal, endocrinologic, oncologic, hemotologic and immunologic disorders which investigators judge to affect on the study significantly. Patients' rejection Pregenancy or lactation

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active group<br>Patients with perennial allergic rhinitis who receive concomitant intranasal antihistamine and corticosteroid. | Drug: concomitant intranasal antihistamine and corticosteroid<br>* concomitant intranasal administration with antihistamine and corticosteroid<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| TNSS | total nasal symptom score | 2 week | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| TOSS | total nasal symptom score | 2 week | 
| RQLQ | rhinoconjunctivitis quality-of-life questionnares | 2 week | 
| VAS | visual analogue scale | 2 week |